Chroma Medicine: Dr. Catherine Stehman-Breen on the Bright Future for Epigenetic Medicine

TL;DR

Chroma is a biotech company focused on epigenetic editing, led by a team of experienced founders and backed by strong investors like Google Ventures. The company aims to develop transformative therapies for a range of diseases by regulating gene expression.

Transcript

as you know gv's mission is to support Innovative Founders moving the world forward and specifically on the life science team we look for technologies that could be potentially transformative for treatment of disease and patients so chroma clearly fits all those criteria how did it all start how did you get involved and what's the story behind it I... Read More

Key Insights

• 🤫 Chroma's focus on epigenetic editing aligns with its goal of regulating gene expression to mitigate disease. The ability to activate or silence genes offers potential for addressing complex diseases.
• 😤 The company has a strong emphasis on building a solid foundation, both in terms of technology and team, to ensure success in the long run.
• 😤 Chroma recognizes the importance of culture in driving innovation and attracting and retaining talented team members.
• 😑 Genomic medicine is a rapidly evolving field with various modalities, including epigenetic editing, gene therapy, and mRNA. Epigenetic editing offers a unique niche in regulating gene expression.
• 🚚 Challenges in epigenetic editing include understanding the technology's impact on biology, defining safety profiles, addressing delivery to different tissues, and gaining support from payers.
• 🧡 Chroma aims to strategically expand its capabilities through partnerships to overcome challenges in tissue delivery and access to a wider range of diseases.
• 💪 Over the next five years, Chroma plans to demonstrate compelling data in patients, expand its capabilities, and establish a strong foothold in the field of genomic medicine.

Questions & Answers

Q: How did Chroma start and what attracted the CEO to join the company?

Chroma began with a call from David Liu, and the current CEO, who was already contemplating becoming a CEO at a startup, found the opportunity intriguing. The CEO was particularly interested in joining because of the strong team, idea, and early investors involved.

Q: How does Chroma leverage its high-profile founders?

Chroma has six illustrious founders, including experts in the field of epigenetic editing. The team was expanded through the acquisition of Epsilon. The founders work together effectively and support Chroma's mission.

Q: How was Chroma able to secure substantial funding in a difficult financing environment?

Chroma attributes its successful fundraising to key strengths, such as a compelling vision, promising science, a strong team, and supportive investors like Google Ventures. The company's track record of delivering on its plans and having a planful approach also played a role in securing funding.

Q: What motivated the CEO to transition from academia to industry?

The CEO was initially an academic researcher but was recruited for a job at Amgen. The decision to join the industry was driven by the energy, excitement, and collaborative atmosphere observed during the interview process. The CEO found fulfillment in developing therapeutics that could have a broad impact on patients' lives.

Summary & Key Takeaways

• Chroma was formed around the idea of epigenetic editing, sparked by a call from David Liu to the current CEO. The company has a strong team, early investors, and a compelling vision.

• Chroma's team includes six founders, including experts in epigenetics, acquired through the acquisition of a small Italian company called Epsilon.

• The company has successfully raised two rounds of funding, totaling $250 million, despite the challenging financing environment.